Jan 07, 2019 Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
Nov 02, 2018 Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Sep 25, 2018 Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101
Sep 06, 2018 Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
Aug 30, 2018 Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 13, 2018 Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
Aug 07, 2018 Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights